The problem with your post is the word "Unique". You give a lot of cellular physiology/pathophysiology and some physiology of the S1R as background...we can ignore that relative to the "unique" aspect. Unfortunately, there is absolutely nothing unique expected from 2-73 in what you wrote (or in general). Let's examine specifics...
This statement is not supported nor is it supportable. There are many S1R agonists and AVXL has not presented any data to suggest 2-73 agonizes in a unique manner.
All of this is “homeostatic,” creating “homeostasis” within the neuron (and nerve).
This is a normal function of the S1R and if you look at the references AVXL provides in their presentations where they note homeostasis you will see they relate to S1R function and S1R agonists other than 2-73. So again, nothing unique for 2-73. Same goes for blocking NOS, neuroprotection, modulating Ca++, reducing mitochondrial dysfunction, reducing protein misfolding, reducing oxidative stress, and reducing inflammation. ALL generic S1R functions.
There are no existing drugs that have this MOA, nor are able to restore neuron homeostasis.
There are many drugs that include that MOA. Nothing unique to 2-73 action has been shown to confer any advantage.
In light of the above, please point to any aspect of your post you still feel is unique...I don't believe there is anything.
Market Data 
Markets 
AI
